<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2664-3243</journal-id>
<journal-title><![CDATA[Vive Revista de Salud]]></journal-title>
<abbrev-journal-title><![CDATA[Vive Rev. Salud]]></abbrev-journal-title>
<issn>2664-3243</issn>
<publisher>
<publisher-name><![CDATA[CET-BOLIVIA]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2664-32432023000100251</article-id>
<article-id pub-id-type="doi">10.33996/revistavive.v6i16.223</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Hipertensión arterial, un reto farmacológico]]></article-title>
<article-title xml:lang="en"><![CDATA[Arterial hypertension, a pharmacological challenge]]></article-title>
<article-title xml:lang="pt"><![CDATA[Hhipertensão arterial, um desafio farmacológico]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Moscoso]]></surname>
<given-names><![CDATA[Marco Antonio Chalco]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Suárez]]></surname>
<given-names><![CDATA[Alicia Esperanza Zhingre]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Católica de Cuenca  ]]></institution>
<addr-line><![CDATA[Cuenca ]]></addr-line>
<country>Ecuador</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2023</year>
</pub-date>
<volume>6</volume>
<numero>16</numero>
<fpage>251</fpage>
<lpage>263</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_arttext&amp;pid=S2664-32432023000100251&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_abstract&amp;pid=S2664-32432023000100251&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_pdf&amp;pid=S2664-32432023000100251&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN La hipertensión arterial (HTA) es una enfermedad crónica que afecta a más del 30% de la población adulta en todo el mundo y se caracteriza por tener una presión arterial más alta de lo normal. Se presentan los principales fármacos para el correcto manejo de la enfermedad según la gravedad de los síntomas del paciente evaluado por SCORE de riesgo cardiovascular y por sus patologías concomitantes. Objetivo. Identificar los fármacos y el tipo de tratamiento, farmacológico o no farmacológico, empleados en la HTA en cuanto a su diagnóstico, mejorando el manejo del paciente que padece esta enfermedad. Metodología. Se realizó una revisión de tipo sistemática empleando el protocolo PRISMA para la recopilación de información en trabajos procedentes de motores de búsqueda como PubMed, Scopus, Web of Science y ELSEVIER sobre el tratamiento de la Hipertensión Arterial Primaria, publicados durante enero del año 2017 hasta diciembre del año 2022. Conclusión. La hipertensión arterial sigue siendo un reto en el campo de la farmacología debido a su alta prevalencia y su asociación con múltiples enfermedades cardiovasculares. Los tratamientos disponibles son efectivos, pero no curan la enfermedad, por lo que es necesario seguir investigando nuevas opciones terapéuticas para mejorar el control y reducir el impacto en la salud pública. La educación y la prevención son herramientas importantes para reducir la incidencia de hipertensión y mejorar el manejo de la enfermedad. Con esta investigación fue posible identificar la importancia del tratamiento farmacológico y el tratamiento de tipo no farmacológico, evaluando adecuadamente el estado del paciente.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT Arterial hypertension (AHT) is a chronic disease that affects more than 30% of the adult population worldwide and is characterized by higher than normal blood pressure. The main drugs for the correct management of the disease are presented according to the severity of the patient's symptoms evaluated by SCORE of cardiovascular risk and by his concomitant pathologies. Objective. To identify the drugs and the type of treatment, pharmacological or non-pharmacological, used in HT in terms of its diagnosis, improving the management of the patient suffering from this disease. Methodology. A systematic review was performed using the PRISMA protocol for the collection of information in works from search engines such as PubMed, Scopus, Web of Science and ELSEVIER on the treatment of Primary Arterial Hypertension, published during January 2017 until December 2022. Conclusion. Arterial hypertension remains a challenge in the field of pharmacology due to its high prevalence and association with multiple cardiovascular diseases. Available treatments are effective, but do not cure the disease, so it is necessary to continue investigating new therapeutic options to improve control and reduce the impact on public health. Education and prevention are important tools to reduce the incidence of hypertension and improve disease management. With this research it was possible to identify the importance of pharmacological treatment and non-pharmacological treatment, adequately assessing the patient's condition.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[RESUMO A hipertensão arterial (HTA) é uma doença crônica que afeta mais de 30% da população adulta em todo o mundo e é caracterizada por pressão arterial acima do normal. Os principais medicamentos para o correto manejo da doença são apresentados de acordo com a gravidade dos sintomas do paciente, conforme avaliado pelo SCORE, risco cardiovascular e patologias concomitantes. Objetivo. Identificar os medicamentos e o tipo de tratamento, farmacológico ou não farmacológico, utilizados na hipertensão arterial em termos de seu diagnóstico, melhorando o manejo do paciente que sofre dessa doença. Metodologia. Foi realizada uma revisão sistemática utilizando o protocolo PRISMA para a coleta de informações em trabalhos de mecanismos de busca como PubMed, Scopus, Web of Science e ELSEVIER sobre o tratamento da Hipertensão Arterial Primária, publicados de janeiro de 2017 a dezembro de 2022. Conclusões. A hipertensão arterial continua sendo um desafio no campo da farmacologia devido à sua alta prevalência e associação com várias doenças cardiovasculares. Os tratamentos disponíveis são eficazes, mas não curam a doença, portanto, são necessárias mais pesquisas sobre novas opções terapêuticas para melhorar o controle e reduzir o impacto na saúde pública. A educação e a prevenção são ferramentas importantes para reduzir a incidência de hipertensão e melhorar o controle da doença. Com essa pesquisa, foi possível identificar a importância do tratamento farmacológico e do tratamento não farmacológico, avaliando adequadamente a condição do paciente.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Hipertensión]]></kwd>
<kwd lng="es"><![CDATA[Quimioterapia]]></kwd>
<kwd lng="es"><![CDATA[Hábitos]]></kwd>
<kwd lng="es"><![CDATA[Monitoreo Ambulatorio]]></kwd>
<kwd lng="en"><![CDATA[Hypertension]]></kwd>
<kwd lng="en"><![CDATA[Drug Therapy]]></kwd>
<kwd lng="en"><![CDATA[Habits]]></kwd>
<kwd lng="en"><![CDATA[Monitoring Ambulatory]]></kwd>
<kwd lng="pt"><![CDATA[Hipertensão]]></kwd>
<kwd lng="pt"><![CDATA[Tratamento Farmacológico]]></kwd>
<kwd lng="pt"><![CDATA[Hábitos]]></kwd>
<kwd lng="pt"><![CDATA[Monitorização Ambulatorial]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jordan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kurschat]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Reuter]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Arterial Hypertension.]]></article-title>
<source><![CDATA[Dtsch Arztebl Int.]]></source>
<year>2018</year>
<volume>115</volume>
<numero>33</numero>
<issue>33</issue>
<page-range>557-68</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vangen-Lønne]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Wilsgaard]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Johnsen]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Løchen]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Njølstad]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Mathiesen]]></surname>
<given-names><![CDATA[EB.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Declining Incidence of Ischemic Stroke: ¿What Is the Impact of Changing Risk Factors? The Tromsø Study 1995 to 2012]]></article-title>
<source><![CDATA[Stroke]]></source>
<year>2017</year>
<volume>48</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>544-50</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gao]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Cai]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2020</year>
<volume>41</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>2058-66</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Al Ghorani]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Götzinger]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Böhm]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mahfoud]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Arterial hypertension - Clinical trials update 2021]]></article-title>
<source><![CDATA[Nutr Metab Cardiovasc Dis.]]></source>
<year>2022</year>
<volume>32</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>21-31</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tousoulis]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Arterial hypertension: ¿New concepts in diagnosis and treatment?]]></article-title>
<source><![CDATA[Hellenic J Cardiol]]></source>
<year>2020</year>
<volume>61</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>145-7</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Mancia]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Spiering]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2018 ESC/ESH Guidelines for the management of arterial hypertension]]></article-title>
<source><![CDATA[Eur Heart J.]]></source>
<year>2019</year>
<volume>40</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Flack]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Adekola]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Blood pressure and the new ACC/AHA hypertension guidelines.]]></article-title>
<source><![CDATA[Trends Cardiovasc Med]]></source>
<year>2020</year>
<volume>30</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>160-4</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gyöngyösi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[K&#337;rösi]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Batta]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of Different Cardiovascular Risk Score and Pulse Wave Velocity-Based Methods for Vascular Age Calculation.]]></article-title>
<source><![CDATA[Heart Lung Circ.]]></source>
<year>2021</year>
<volume>30</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1744-51</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Manosroi]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[GH.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Genetics of Human Primary Hypertension: Focus on Hormonal Mechanisms.]]></article-title>
<source><![CDATA[Endocr Rev.]]></source>
<year>2019</year>
<volume>40</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>825-56</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Topel]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Duncan]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Krishna]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Badell]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Vaccarino]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Quyyumi]]></surname>
<given-names><![CDATA[AA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estimated Impact of the 2017 American College of Cardiology/American Heart Association Blood Pressure Guidelines on Reproductive-Aged Women.]]></article-title>
<source><![CDATA[Hypertension]]></source>
<year>2018</year>
<volume>72</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>e39-42</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<collab>Blood Pressure Lowering Treatment Trialists&#8217; Collaboration</collab>
<article-title xml:lang=""><![CDATA[Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis]]></article-title>
<source><![CDATA[Lancet]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stergiou]]></surname>
<given-names><![CDATA[GS]]></given-names>
</name>
<name>
<surname><![CDATA[Kario]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kollias]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Home blood pressure monitoring in the 21st century.]]></article-title>
<source><![CDATA[J Clin Hypertens (Greenwich)]]></source>
<year>2018</year>
<volume>20</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1116-21</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roerecke]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kaczorowski]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Myers]]></surname>
<given-names><![CDATA[MG.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparing Automated Office Blood Pressure Readings With Other Methods of Blood Pressure Measurement for Identifying Patients With Possible Hypertension: A Systematic Review and Meta-analysis.]]></article-title>
<source><![CDATA[JAMA Intern Med.]]></source>
<year>2019</year>
<volume>179</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>351-62</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Camafort]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Alcocer]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Coca]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Latin-American Ambulatory Blood Pressure Registry (MAPA-LATAM): An urgent need.]]></article-title>
<source><![CDATA[Rev Clin Esp (Barc)]]></source>
<year>2021</year>
<volume>221</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>547-52</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sabbahi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Severin]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Laddu]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Sharman]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Arena]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ozemek]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nonpharmacological Management of Resistant Hypertension]]></article-title>
<source><![CDATA[Curr Cardiol Rep]]></source>
<year>2021</year>
<volume>23</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>166</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kucharska]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gajewska]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Kiedrowski]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The impact of individualised nutritional therapy according to DASH diet on blood pressure, body mass, and selected biochemical parameters in overweight/obese patients with primary arterial hypertension: a prospective randomised study]]></article-title>
<source><![CDATA[Kardiol Pol.]]></source>
<year>2018</year>
<volume>76</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>158-65</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heidenreich]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Bozkurt]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilar]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2022</year>
<volume>79</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>1757-80</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Teo]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
<name>
<surname><![CDATA[Rafiq]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular Risk Factors and Prevention: A Perspective From Developing Countries]]></article-title>
<source><![CDATA[Can J Cardiol]]></source>
<year>2021</year>
<volume>37</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>733-43</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Verdecchia]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Reboldi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Angeli]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The 2020 International Society of Hypertension global hypertension practice guidelines - key messages and clinical considerations.]]></article-title>
<source><![CDATA[Eur J Intern Med]]></source>
<year>2020</year>
<page-range>1-6</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Acelajado]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Hughes]]></surname>
<given-names><![CDATA[ZH]]></given-names>
</name>
<name>
<surname><![CDATA[Oparil]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Calhoun]]></surname>
<given-names><![CDATA[DA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of Resistant and Refractory Hypertension]]></article-title>
<source><![CDATA[Circ Res]]></source>
<year>2019</year>
<volume>124</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1061-70</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Judd]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Calhoun]]></surname>
<given-names><![CDATA[DA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Apparent and true resistant hypertension: definition, prevalence and outcomes]]></article-title>
<source><![CDATA[J Hum Hypertens]]></source>
<year>2014</year>
<volume>28</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>463-8</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seccia]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Caroccia]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Maiolino]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cesari]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rossi]]></surname>
<given-names><![CDATA[GP.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Arterial Hypertension, Aldosterone, and Atrial Fibrillation.]]></article-title>
<source><![CDATA[Curr Hypertens Rep]]></source>
<year>2019</year>
<volume>21</volume>
<numero>12</numero>
<issue>12</issue>
</nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sinha]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Agarwal]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical Pharmacology of Antihypertensive Therapy for the Treatment of Hypertension in CKD]]></article-title>
<source><![CDATA[Clin J Am Soc Nephrol]]></source>
<year>2019</year>
<volume>14</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>757-64</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gallo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Volpe]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rubattu]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Angiotensin Receptor Blockers in the Management of Hypertension: A Real-World Perspective and Current Recommendations]]></article-title>
<source><![CDATA[Vasc Health Risk Manag]]></source>
<year>2022</year>
<page-range>507-15</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Danaietash]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Verweij]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Identifying and treating resistant hypertension in PRECISION: A randomized long-term clinical trial with aprocitentan]]></article-title>
<source><![CDATA[J Clin Hypertens (Greenwich)]]></source>
<year>2022</year>
<volume>24</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>804-13</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oparil]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Acelajado]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Bakris]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertension]]></article-title>
<source><![CDATA[Nat Rev Dis Primers]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vargas-Uricoechea]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Cáceres-Acosta]]></surname>
<given-names><![CDATA[MF.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Control of Blood Pressure and Cardiovascular Outcomes in Type 2 Diabetes]]></article-title>
<source><![CDATA[Open Med (Wars)]]></source>
<year>2018</year>
<page-range>304-23</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Ma]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Cao]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Yan]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of thiazide-like diuretics versus thiazide-type diuretics: a meta-analysis.]]></article-title>
<source><![CDATA[J Cell Mol Med]]></source>
<year>2017</year>
<volume>21</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2634-42</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fragakis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mannan]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ho]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association between Drug Usage and Constipation in the Elderly Population of Greater Western Sydney Australia.]]></article-title>
<source><![CDATA[Int J Environ Res Public Health]]></source>
<year>2018</year>
<volume>15</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wiysonge]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Bradley]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Mayosi]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Beta-blockers for hypertension.]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2007</year>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shuey]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Perkins]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Nian]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Luther]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Retrospective cohort study to characterise the blood pressure response to spironolactone in patients with apparent therapy-resistant hypertension using electronic medical record data]]></article-title>
<source><![CDATA[BMJ Open]]></source>
<year>2020</year>
<volume>10</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carone]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Oxberry]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
<name>
<surname><![CDATA[Twycross]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Charlesworth]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mihalyo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wilcock]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Spironolactone]]></article-title>
<source><![CDATA[J Pain Symptom Manage]]></source>
<year>2017</year>
<volume>53</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>288-92</page-range></nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of Cardiovascular Risk in Perimenopausal Women with Diabetes]]></article-title>
<source><![CDATA[Diabetes Metab J]]></source>
<year>2021</year>
<volume>45</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>492-501</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
